Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Daiichi Sankyo: Sales Down 5.3% due to One-time Effects of Merger
May 26, 2008
- I'rom to Market Ranbaxy's Generic Amlodipine
May 26, 2008
- Astellas: Tough Year Expected in FY2008 due to Prograf Patent Expiration
May 26, 2008
- Will Generics Take Off? (4)
May 26, 2008
- Takeda's R&D Spending to Hit Record High of \485 Bil. in FY2008
May 26, 2008
- BUSINESS NEWS IN BRIEF
May 26, 2008
- Takeda Completes Acquisition of Millennium
May 26, 2008
- Toho Pharm.: Record-High Sales and Profits
May 26, 2008
- Kyowa Hakko Kirin Aims at Becoming Global Specialty Pharma Leveraging Biotechnology
May 26, 2008
- Suzuken: Sales Up 8.7% for Wholesale Business
May 26, 2008
- All-Patient Survey Confirms Enbrel's Safety, Efficacy
May 26, 2008
- Alfresa: Sales Up 11.3% to \1,769 Bil.
May 26, 2008
- Mediceo Paltac: Sales Up 4.1% to \2,255 Bil.
May 26, 2008
- Divergent Opinions on Japanese Version of FDA among LDP Members
May 19, 2008
- Daiichi Sankyo to Apply for Combination of Olmetec and Calblock
May 19, 2008
- Banyu's Isentress Roughly Recommended for Approval
May 19, 2008
- MEDICAL DEVICE NEWS IN BRIEF
May 19, 2008
- Committee Recommends Approval of Pfizer's Macugen
May 19, 2008
- R&D NEWS IN BRIEF
May 19, 2008
- BUSINESS NEWS IN BRIEF
May 19, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…